AnalystsJames Condulis
James Condulis's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Top 36%
#1970 out of 5510 analysts
Average Return
+6.83%
Win Rate
50%7 out of 14
Risk vs Reward
Poor
Good

James Condulis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Amylyx Pharmaceuticals IncAMLX
+138.41%$14.11$33.64
2026-03-03 -
2026-09-14
Strong Buy
Cytokinetics IncCYTK
+43.89%$49.62$71.40
2025-09-02 -
2026-09-01
Strong Buy
Newamsterdam Pharma Co NvNAMS
+39.10%$21.84$30.38
2025-06-10 -
2026-06-09
Strong Buy
Cytokinetics IncCYTK
+34.64%$46.82$63.04
2025-01-22 -
2026-01-21
Strong Buy
Arrowhead Pharmaceuticals IncARWR
+12.18%$71.91$80.67
2026-07-14 -
2026-09-14
Strong Buy

James Condulis Analyst Color

Get additional color on James Condulis's coverage of popular stocks

James Condulis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Braveheart Bio IncBRVE
1Strong Buy$45.00+66.54%Initiates Coverage On
15 days ago
Arrowhead Pharmaceuticals IncARWR
1Strong Buy$98.00+21.48%Initiates Coverage On
2 months ago
Fulcrum Therapeutics IncFULC
1Hold$3.00-20.84%Downgrades
3 months ago
Cytokinetics IncCYTK
3Strong Buy$108.00+49.07%Maintains
4 months ago
Mirum Pharmaceuticals IncMIRM
1Strong Buy$130.00+34.37%Maintains
5 months ago
Tectonic Therapeutic IncTECX
1Strong Buy$75.00+152.44%Initiates Coverage On
5 months ago
Amylyx Pharmaceuticals IncAMLX
1Strong Buy$21.00-37.57%Initiates Coverage On
6 months ago
Aardvark Therapeutics IncAARD
2Hold$6.00+8.11%Downgrades
6 months ago
Newamsterdam Pharma Co NvNAMS
2Strong Buy$50.00+123.61%Maintains
9 months ago
X4 Pharmaceuticals IncXFOR
1Strong Buy$10.00+176.24%Maintains
9 months ago
Soleno Therapeutics IncSLNO
2Strong Buy$108.00N/AMaintains
a year ago
Edgewise Therapeutics IncEWTX
1Hold$30.00N/AInitiates Coverage On
2 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.